Brammer Bio Revenue and Competitors
Estimated Revenue & Valuation
- Brammer Bio's estimated annual revenue is currently $17.7M per year.
- Brammer Bio's estimated revenue per employee is $201,000
- Brammer Bio has 88 Employees.
- Brammer Bio grew their employee count by -16% last year.
What Is Brammer Bio?
Brammer Bio is a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies. Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts. Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. The Brammer team consists of extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients. We are Helping to Cure.® The management team is led by President and CEO Mark Bamforth; Chief Scientific Officer Dr. Richard Snyder, the founder of Florida Biologix, which was spun out of the University of Florida in 2015; and Chief Operating Officer Christopher Murphy. Brammer Bio offers a competitive benefits package, including medical, dental, vision, paid time off, holidays, 401(k) with a company match, incentive bonus, flexible spending account (FSA), and educational assistance.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Brammer Bio News
Novasep, Brammer Bio, Lonza, Cobra Biologics, Oxford Biomedica, Finvector Vision Therapies, Merck KGaA, Spark Therapeutics, uniQure, Merck.
... Market May See Potentially High Growth Factors, Explore by Top Players Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult.
KG, Brammer Bio, LLC, Creative Biogene, GE Healthcare, Pfizer Inc. and Sanofi S.A.. The report provides a good overview of the key...
“Global Viral Vector Development Service Market 2019 – Kaneka Eurogentec , FinVector , Brammer Bio , Cell and Gene rapy Catapult “.
Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|